SABCS 2023: Latest breast cancer diagnostics guidelines
Prof Tibor Kovács speaks to ecancer at BGICC 2019 in Cairo about sentinel lymph node biopsy following neoadjuvant chemotherapy.
He explains that, in the neoadjuvant setting, sentinel lymph node biopsy can still be performed and has several advantages such as reducing complications from axillary lymph node clearance.
Prof Kovács explains that studies have shown that SLNB can be performed after neoadjuvant chemotherapy despite patients having a more advanced disease and even with patients previously being node positive.
My presentation later today is going to be about sentinel lymph node biopsies following neoadjuvant chemotherapy for breast cancer patients. As you will know, sentinel lymph node biopsy is a standard procedure for patients who undergo breast cancer surgery prior to neoadjuvant chemotherapy and there is this other setting when patients, for a certain reason, for down-staging for downsizing, they will require neoadjuvant preoperative chemotherapy. Sentinel node biopsy can still be performed and it has certain advantages such as sparing the complications relating to axillary lymph node clearances. Complications with axillary lymph node clearances are quite high, 30-40%, such as lymphedema. With a sentinel lymph node biopsy patients will have far less, around 6%, this is why it is so important to keep this procedure as an option for those patients who require neoadjuvant chemotherapy.
The reason why this is a little bit of a more challenging area of cancer surgery is because it was supposed that patients who have more advanced disease, perhaps with involved lymph nodes, and they receive neoadjuvant chemotherapy that sentinel lymph node biopsy performed after neoadjuvant chemotherapy might not be that reliable. Studies have shown that the method is efficient, it can be performed after neoadjuvant chemotherapy even for patients who previously had been node positive. There is also the technique of targeted axillary dissection which can be associated with the sentinel lymph node biopsy in order to increase the identification rates and to avoid any false negatives.
It is already, I would say, standard of care for those patients who are node negative prior to neoadjuvant chemotherapy and they can have sentinel lymph node biopsy with a low false negative rate and high identification rate. For those patients who are positive before neoadjuvant chemotherapy and they become negative following neoadjuvant chemotherapy the method can be safely performed, it is feasible. The added value of the targeted axillary dissection is something which we have to count really.
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Somatic mutation profile of breast cancer in Uganda
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
Overview of the management of HER2-low breast cancer patients